A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Chu, Ya, Shi, Guangjiang, Wang, Xiaobin, Ye, Wanli, Shan, Chun, Wang, Dajia, Zhang, Di, He, Wei, Jiang, Jingwei, Ma, Shuqian, Han, Yuhong, Zhao, Zhili, Du, Shijia, Chen, Zhen, Li, Zhiyu, Yang, Yong, Wang, Chen, Xu, Xi, Wu, Hongxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643156/
https://www.ncbi.nlm.nih.gov/pubmed/36386477
http://dx.doi.org/10.1016/j.apsb.2022.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643156/
https://www.ncbi.nlm.nih.gov/pubmed/36386477
http://dx.doi.org/10.1016/j.apsb.2022.05.003

Ejemplares similares